Extended Data Figure 2 : Additional characterization of eCD4-Ig.

From: AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

Extended Data Figure 2

a, b, Experiments similar to those of Fig. 1b except that CD4-Ig (red), fusion1 (grey), fusion2 (green) and fusion3 (eCD4-Ig; blue) are compared using HIV-1 pseudotyped with the envelope glycoproteins of the 89.6 (a) or ADA (b) isolates. c, d, Experiments similar to those in Fig. 1e except that CD4-Ig (red), eCD4-Ig (blue) or heterodimers thereof (grey) are compared. e, CD4-Ig, eCD4-Ig and the CD4-Ig/eCD4-Ig heterodimer assayed in c, d and Fig. 1e were analysed by SDS–PAGE and stained with Coomassie blue under reducing (left) and non-reducing (right) conditions. f, g, Infectious 89.6 (f) or SG3 (g) HIV-1 was incubated with human PBMC in the presence of the indicated concentrations of CD4-Ig (red) or eCD4-Ig (blue), or without either inhibitor (grey). Culture supernatants were collected on the indicated day and viral p24 levels were measured by ELISA. h, Viral loads in RNA copies ml−1 are shown for each humanized mouse of Fig. 1f. Mice treated with eCD4-Ig are indicated with blue lines and mice treated with PBS are indicated with red lines. The 800 copies ml−1 limit of detection of this assay is indicated by a dashed line. Experiments in ag were performed at least twice with similar results. Error bars denote s.e.m. of triplicates.